» Articles » PMID: 37112658

The Effect of the Immunization Schedule and Antibody Levels (Anti-S) on the Risk of SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers in Northern Italy

Abstract

Given their occupational risk profile, HCWs were the first to receive anti-SARS-CoV-2 vaccination. However, breakthrough infections remained common, mainly sustained by new SARS-CoV-2 variants of concern (VOCs) that rapidly spread one after another in Italy. Evidence suggests that the measured level of anti-SARS-CoV-2 antibodies does not clearly predict the level of protection conferred by either natural infection or vaccine-induced immunization, highlighting the need for further study on the diversity in susceptibility to SARS-CoV-2 infection. The present study aimed to characterize different risk profiles for SARS-CoV-2 infection in HCWs who had recently received the booster dose, and who were classified according to their immunization profile. The very small number of workers infected during the 8 months following the primary-cycle administration represents proof of the vaccine's effectiveness against non-omicron strains. The comparison among different immunization profiles showed that hybrid immunization (vaccine plus natural infection) elicits higher antibody levels. However, hybrid immunization does not always provide better protection against reinfection, thus suggesting that the immunization profile plays a major role as a virus-host interaction modifier. Despite the high resistance to the reinfection, the peri-booster infection had a not-neglectable infection rate (5.6%), this further reinforcing the importance of preventive measures.

Citing Articles

Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project.

Spiteri G, DAgostini M, Abedini M, Ditano G, Collatuzzo G, Boffetta P Infection. 2024; 52(4):1347-1356.

PMID: 38326526 PMC: 11289150. DOI: 10.1007/s15010-024-02189-x.


Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers-ORCHESTRA Project.

Leomanni L, Collatuzzo G, Sansone E, Sala E, De Palma G, Porru S Vaccines (Basel). 2023; 11(10).

PMID: 37896931 PMC: 10610704. DOI: 10.3390/vaccines11101527.


How European Research Projects Can Support Vaccination Strategies: The Case of the ORCHESTRA Project for SARS-CoV-2.

Azzini A, Canziani L, Davis R, Mirandola M, Hoelscher M, Meyer L Vaccines (Basel). 2023; 11(8).

PMID: 37631929 PMC: 10459328. DOI: 10.3390/vaccines11081361.


Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.

Ruggieri S, Aiello A, Tortorella C, Navarra A, Vanini V, Meschi S Int J Mol Sci. 2023; 24(10).

PMID: 37239872 PMC: 10218688. DOI: 10.3390/ijms24108525.

References
1.
Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

2.
Van Damme P, Moiseeva A, Marichev I, Kervyn A, Booy R, Kuriyakose S . Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infect Dis. 2010; 10:357. PMC: 3016379. DOI: 10.1186/1471-2334-10-357. View

3.
Abu-Raddad L, Chemaitelly H, Ayoub H, Yassine H, Benslimane F, Al Khatib H . Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA. 2021; 326(19):1930-1939. PMC: 8561432. DOI: 10.1001/jama.2021.19623. View

4.
Sansone E, Sala E, Albini E, Tiraboschi M, Cipriani L, De Palma G . Effectiveness of a digital data gathering system to manage the first pandemic wave among healthcare workers in a main European coronavirus disease 2019 (COVID-19) tertiary-care hospital. Antimicrob Steward Healthc Epidemiol. 2022; 2(1):e66. PMC: 9726499. DOI: 10.1017/ash.2022.48. View

5.
Israel A, Merzon E, Schaffer A, Shenhar Y, Green I, Golan-Cohen A . Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ. 2021; 375:e067873. PMC: 9083235. DOI: 10.1136/bmj-2021-067873. View